June 11, 2026
In response to the evolving prognosis for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), Mayo Clinic physicians are implementing strategies for treatment de-escalation. However, optimization of those strategies and treatment outcomes requires more than an evidence-based dosage plan for adjuvant therapy.
Advanced technology, a multidisciplinary approach and surgical expertise help Mayo Clinic physicians individualize treatment and achieve disease control with reduced side effects.
"Quality of life is a prominent concern when patients seek our opinion and care," says Samip Patel, M.D., a head and neck surgeon at Mayo Clinic in Jacksonville, Florida. "Our approach has to be comprehensive and go beyond de-escalation. We use precision medicine and multidisciplinary expertise to determine the optimal treatment pathway and amount of therapy for each individual."
4 critical factors for optimal HPV-positive OPSCC treatment de-escalation
Mayo Clinic researchers continue to play a pivotal role in establishing treatment de-escalation strategies for HPV-positive (HPV+) OPSCC, specifically de-escalated adjuvant radiation therapy (DART). Mayo Clinic research published in The Lancet Oncology reports on a randomized phase 3 study comparing standard treatment and DART following transoral robotic surgery (TORS) in 228 patients.
Patients in the DART cohort (randomized 2:1) received a two-week course of daily de-escalated adjuvant radiation therapy (30 to 36 Gy) plus intravenous docetaxel administered on days one and eight. All other patients received standard of care, which includes a higher dose of radiation therapy (60 Gy) administered daily for six weeks plus intravenous cisplatin once a week. The findings demonstrated that DART significantly reduces grade 2 and grade 3 toxicities compared with standard treatment.
However, treatment duration and dosage are not the only factors positively affecting outcomes. Other critical factors in Mayo Clinic's de-escalation strategy include:
-
Identification of circulating tumor HPV DNA using liquid biopsy
Standard of care for the initial diagnosis of HPV+ OPSCC remains tissue biopsy and pathology confirmation with p16 immunohistochemistry. However, the role of liquid biopsy is growing in prevalence as a less invasive alternative that eliminates sample bias and enables dynamic disease monitoring.
Mayo Clinic physicians monitor circulating tumor HPV DNA (ctHPVDNA) postoperatively or posttherapy using liquid biopsy testing and analysis provided through Mayo Clinic Laboratories.
Access to in-house testing provides cost-effective and quick results, leading to earlier and de-escalated treatment when appropriate. Following surgery or therapy, liquid biopsies are ordered every three months for the first two years, and every six months after that.
"Liquid biopsy may enable us to diagnose patients with positive circulating tumor DNA up to 6 to 8 months earlier than it appears on imaging," says Dr. Patel.
Most centers, including Mayo Clinic, are currently using the test as binary, and researchers are working to understand the specifics of the assessment and how they might guide personalized treatment. Though ctHPVDNA is predictive of the current cancer state, questions remain surrounding the prognostication of ctHPVDNA.
"Blood drawn the day after surgery shows ctHPVDNA to be undetectable 80% to 90% of the time," says Dr. Patel. "But can we make treatment decisions based on that alone? Not yet."
-
Multidisciplinary approach to personalized treatment
Understanding how to optimally personalize treatment for patients with HPV+ OPSCC, including strategies for de-escalation, remains challenging. Mayo Clinic addresses that challenge by employing multidisciplinary collaboration at all stages.
"Most patients we diagnose with HPV+ oropharyngeal cancer have low-risk or intermediate-to-low-risk cancers, and we expect to cure those patients," says Dr. Patel. Offering the viewpoints of a surgeon, medical oncologist and radiation oncologist can be critical in helping those patients make informed treatment decisions.
But there are outliers. Complex and advanced cancer cases require a high level of multidisciplinary expertise to individualize and de-escalate the approach to still achieve optimal outcomes. De-escalation strategies for patients who are not surgical candidates require close collaboration and monitoring.
"How to personalize treatment for these patients is the million-dollar question," says Dr. Patel. "There are trials around the world trying to answer that question. The backbone for Mayo Clinic's approach is comprehensive multidisciplinary expertise and careful monitoring of ctHPVDNA kinetics during treatment."
-
Nuanced approach to transoral robotic surgery for HPV+ OPSCC
TORS can play an essential role in treatment de-escalation. In clinically appropriate patients, it offers an alternative to toxic therapies and access to pathology that can identify low- versus high-risk features within the primary tumor or lymph nodes. Therefore, there is a potential for downstaging or upstaging patients based on the final pathology obtained from surgery.
Navigating the complexities associated with TORS and HPV+ OPSCC can require expertise gained from volume and experience. Considerations for risk stratification include:
- Patient health and comorbidities.
- Disease burden.
- Exposure to the throat and tumor.
- Tumor volume.
"Treating patients surgically, if appropriate, naturally results in less toxicity," says Dr. Patel. "If we can also reduce the postoperative dose of radiation and chemotherapy and still achieve control, that's the ideal scenario."
-
Collaboration with referring physicians
Mayo Clinic surgeons and oncologists welcome the opportunity to meet with patients who are weighing their treatment options. In addition to standard of care treatment, Mayo Clinic offers access to clinical trials and novel approaches.
"The most important thing is to get the patient all the information to understand their options and make an informed decision about their treatment," says Dr. Patel. "In some cases, that decision involves surgery at Mayo Clinic and then adjuvant therapy closer to home. That's when building a relationship with the referring physician is especially critical."
"Our approach has to be comprehensive and go beyond de-escalation. We use precision medicine and multidisciplinary expertise to determine the optimal treatment pathway and amount of therapy for each individual."
Evolving treatment paradigms for HPV+ OPSCC
Guidelines for diagnosing and treating HPV+ OPSCC will continue to shift as experts study the available biomarker data and establish new ways to personalize treatment.
"There are many clinical aspects to consider with how we continue to de-escalate treatment for HPV+ OPSCC," says Dr. Patel. "At the forefront is learning more about these tumors and providing appropriate counseling for patients as they process information about their disease and treatment options."
For more information
Ma D, et al. De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): A phase 3, open-label, randomised controlled trial. The Lancet Oncology. 2025;26:1227.
Refer a patient to Mayo Clinic.